Skip to main content

Dr. Jeffrey P. Letzer, DO

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
40
In the NPI registry since
2005
Medicare patients seen, 2024
178

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    IN license 02005703A · MI license 5101010182

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
178
Services billed
796
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes510176
Established patient office or other outpatient visit, 20-29 minutes3329
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes2911
Established patient office or other outpatient visit, 40-54 minutes2715

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 14 payments worth $4,333 in total to this clinician.

By company
Syndax Pharmaceuticals, Inc.$4,078
Secura Bio, Inc.$99.31
Novartis Pharmaceuticals Corporation$83.86
AbbVie Inc.$45.48
Tempus Ai, Inc$26.80
By type
Consulting Fee$2,875
Travel and Lodging$804
Food and Beverage$655

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 27, 2025Syndax Pharmaceuticals, Inc.
Sep 27, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$2,875
Sep 27, 2025Syndax Pharmaceuticals, Inc.
Sep 27, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL · in-kind
$337
Sep 27, 2025Syndax Pharmaceuticals, Inc.
Sep 27, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL · in-kind
$193
Sep 27, 2025Syndax Pharmaceuticals, Inc.
Sep 27, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL · in-kind
$142
Sep 27, 2025Syndax Pharmaceuticals, Inc.
Sep 27, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL
$132

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Indiana →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $65,675 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
    AstraZeneca UK Limited
  • A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
    Novartis Pharmaceuticals Corporation
  • A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First …
    Novartis Pharmaceuticals Corporation
  • A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
    Novartis Pharmaceuticals Corporation
  • A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
    AbbVie Inc. · Active, not recruiting · NCT05451810
  • A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia P…
    Merck Sharp & Dohme LLC
  • M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
    AbbVie Inc.
  • A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
    Incyte Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Fort Wayne

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 27, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1760481766. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.